Esperion to Participate in Upcoming Bank of America Securities 2022 Healthcare Conference
Rhea-AI Summary
Esperion (NASDAQ: ESPR) has announced that its President and CEO, Sheldon Koenig, will present at the Bank of America Securities 2022 Healthcare Conference on May 10, 2022. The event is set to take place at 3:20 PM PT (6:20 PM ET) and will include both a presentation and individual meetings. Investors can access a live audio webcast through the company's website, with a replay available afterwards for 90 days. Esperion focuses on developing effective oral non-statin medications for cholesterol management, aiming to improve patient health outcomes.
Positive
- None.
Negative
- None.
News Market Reaction – ESPR
In the trading session that priced this news, ESPR gained 3.09%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ANN ARBOR, Mich., April 29, 2022 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR), today announced that President and Chief Executive Officer, Sheldon Koenig, will present at the upcoming Bank of America Securities 2022 Healthcare Conference on Tuesday, May 10th, 2022.
| Event: | Bank of America Securities 2022 Healthcare Conference |
| Date: | Tuesday, May 10th, 2022 |
| Format: | Presentation and 1:1 Meetings |
| Time: | 3:20 pm Pacific Time (6:20 pm ET) |
| Webcast: | Link |
A live audio webcast can be accessed on the investor and media section of the Esperion website at https://www.esperion.com/investor-relations/events. Access to the webcast replay will be available approximately two hours after completion of the call and will be archived on the Company's website for approximately 90 days.
Esperion Therapeutics
Esperion works hard to make our medicines easy to get, easy to take and easy to have. We discover, develop and commercialize innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren’t being met by the status quo. Our entrepreneurial team of industry leaders is inclusive, passionate and resourceful. We are singularly focused on managing cholesterol so you can improve your health easily. Esperion is the leader in the development of convenient oral, once-daily non-statin LDL-cholesterol lowering drugs for patients with high levels of bad cholesterol. For more information, please visit www.esperion.com and follow us on Twitter at www.twitter.com/EsperionInc.
Contact:
Corporate Communications
corporateteam@esperion.com
